Roche Halts Development of Obesity Drug Candidate
By Adria Calatayud
Roche Holding said it stopped work on one of its obesity-drug candidates, after clinical-trial data suggested the medicine wouldn't hit internal targets.
The Swiss drugmaker said it returned rights to the medicine, emugrobart, to its majority-owned business Chugai Pharmaceutical, which originally discovered the drug and licensed it to Roche.
"We have made the decision to discontinue development," Roche's pharmaceuticals chief executive, Teresa Graham, said at an event with investors in London on Monday. "We are returning that molecule to Chugai, and Chugai is looking to further development in [spinal muscular atrophy] as well as considering potential outlicensing opportunities."
Roche had previously estimated the drug had potential to reach annual peak sales of between 1 billion and 2 billion Swiss francs ($1.21 billion-$2.41 billion). The company is also developing two obesity injections and a pill, and sees potential for each of them to exceed 3 billion francs in peak sales.
Earlier this year, Roche also halted development on emugrobart for spinal muscular atrophy and facioscapulohumeral muscular dystrophy, two rare genetic conditions that can cause muscle weakness.
Chugai separately said an interim analysis of data from a midstage study indicated clinically meaningful weight loss was unlikely to be achieved. The trial evaluated emugrobart in combination with another medicine in patients with obesity or who were overweight.
The Japanese company said it plans to move several obesity drug candidates into clinical trials over the next few years.
Chugai said it plans to resume development of emugrobart in spinal muscular atrophy, given that it saw a path to launch a late-stage trial based on an analysis of data from earlier trials. The obesity study showed emugrobart was well tolerated and there were no new safety signals, the company added.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
September 28, 2026 08:48 ET (12:48 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States